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The structure and processes of the Pacific Vascular
Symposium 6
Fedor Lurie, MD,a Robert L. Kistner, MD,a Bo Eklof, MD, PhD,a Thomas Wakefield, MD,b and
Anthony Comerota, MD,c Honolulu, Hawaii; Ann Arbor, Mich; and Toledo, OhioFrom its inception in 1993, the Pacific Vascular
Symposium (PVS) was dedicated to progress in the field
of venous diseases. The major challenge at that time was
the absence of a standard methodologic framework for
investigation and description of the patients with chronic
venous diseases. This was addressed by the development
of the CEAP classification by an ad hoc committee of the
American Venous Forum (AVF) in 1994. Consequent
meetings emphasized the utilization of CEAP for all
forms of chronic venous diseases and gradually devel-
oped the case for more aggressive treatments of acute
and chronic venous diseases. These activities substan-
tially contributed to establishing the current standards of
care for patients with venous diseases.
As the field develops and matures, the existing re-
sources became insufficient to sustain growing diversity
of clinical, academic, educational, and organizational
activities. It became clear that prioritization and collab-
oration are acutely needed. Pacific Vascular Symposium
5 (PVS5) took an unusual and complex task to develop a
vision for the field and prioritize activities. During the 4
days of the meeting, the group of experts and industry
partners was guided through a tedious process by a team
of social psychologists. The meeting resulted in an in-
depth analysis of the status of the discipline and formu-
lation of several priority projects. The impact of the
meeting has been significant nationally and internation-
ally. It started new processes of inter-societal activities,
facilitated development of new funding opportunities,
and created collaborations focused on the priority areas
for future developments.
Despite the impressive progress of the last two decades,
venous disease remains under-studied and is severely
under-estimated for its effects on the public health.
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Chronic venous diseases affect over 20% of the adult
population and are more prevalent than coronary artery,
carotid artery, and peripheral artery diseases com-
bined.1-3 Venous ulcer care costs are estimated to exceed
over a billion dollars annually in the United States.
Ignorance of venous disease is appalling even amongst
the physicians in the United States, largely due to lack of
education about the veins.4
Patients with lower extremity ulcers are treated by
numerous practitioners daily in the United States includ-
ing doctors and nurses whose training is from a wide
variety of medical and surgical disciplines. One would
think that the optimal management of venous ulcers had
been solved long ago and that medical practitioners are
fully knowledgeable about effective treatment and pre-
vention. However, nothing could be further from the
truth. There has been no standardization of how to
determine that an ulcer is of venous origin or how to
proceed with definitive treatment once the diagnosis is
confirmed. Venous ulcers are too frequently misdiag-
nosed and the fundamental principles of venous ulcer
treatment are not followed. The fact is that definitive
management of a venous ulcer is still evolving with most
progress occurring over the last few decades. As the
organization and dissemination of recent advances has
yet to occur, these advances are still largely unknown by
front line primary care physicians and even the majority
of specialists.
Recognizing this situation, the organizing commit-
tee of Pacific Vascular Symposium 6 concluded that the
need exists for a unifying global goal to direct the
research and development, education and awareness ac-
tivities, health care priorities, and changes in public
policies. This goal should be achievable, measurable,
understandable, and broad enough to include the whole
spectrum of venous disease. It appeared that the decrease
in the prevalence of venous ulcers could serve as such a
goal.
The feasibility of 50% reduction of the prevalence of
venous ulcers by implementing standard practices has
been demonstrated in a defined population in Sweden.5
The prevalence of venous ulcers is measurable. Appro-
priate treatment of earlier stages of the venous disease
should substantially reduce the incidence of the end
stage (ulcer), and in some cases prevent it completely. A
better treatment of venous disease in patients with inci-
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ing to reduction of ulcer prevalence. Finally, new tech-
nologies, devices, and pharmaceuticals should improve
the long-term outcomes facilitating the decrease in ve-
nous ulcer prevalence.
Based on this analysis, the goal was postulated as a
50% decrease in prevalence of venous ulcers, and the
objective of Pacific Vascular Symposium 6 (PVS6) was to
create a plan of achieving this goal in 10 years.
The postulated goal requires a spectrum of coordi-
nated efforts broader than the actions usually undertaken
by physicians, scientists, and professional societies.
Achieving this goal is not possible without changes in
practices of primary and secondary care physicians, and
healthcare organizations. Further, this may not be pos-
sible without changes in insurance and public policies.
Patients and the medical community need to be aware of
the problem and educated about available solutions. All
these actions should be based on high quality scientific
evidence. Such evidence is not always available and, in
many instances, cannot be generated within our defined
time. Identification and prioritization of gaps in our
knowledge have to be a part of the plan. New resources
should be developed to support the research that ad-
dresses the key priority questions. In the meantime,
lower level evidence and consensus may serve as a tem-
porary basis for recommendations. Development of new
treatments and diagnostics should be directed toward
the common goal. A new form of relationship with
industry needs to be established with mutual respect to
individual interests and coordination of priorities. Devel-
opment of technologies that address the goal of ulcer
prevalence reduction should be defined, endorsed, and
facilitated by the medical community.
The complexity of the task led to modifications in
design of Pacific Vascular Symposium 6 including the
composition of the participating faculty, the structure
and program of the meeting, and the vision of the
post-meeting activities and processes (Fig).
The number of participating experts was limited to a
total of 60, with a combination of expertise in venous
disease, wound care, internal medicine, nursing, vascular
technology, basic science, epidemiology, health care
management, insurance industry, public policies, mar-
keting, industry research and development, and govern-
ment relationships (Appendix, online only).
The structure of the meeting included two colliding
processes aimed to balance the goal-oriented and the
evidence-based approaches. The first process was di-
rected from the global goal toward identification of what
needs to be done to achieve the 50% goal in 10 years. The
second process had an opposite direction that began with
analysis of the present state of knowledge including
identification of established evidence-based actions per-
tinent to the goal to identify the gaps in knowledge that
need to be addressed to complete the needed evidence
that will support practices to achieve the goal. Each of
the two processes commenced at the plenary sessions,continued with the meetings of the four working groups,
and resulted in a consensus at the plenary session.
Prior to the meeting, selected faculty proposed a list
of critical issues that are necessary, sufficient, and feasible
to solve to achieve the 50% reduction of venous ulcer
prevalence in 10 years.
The list was available to all participants, and included
critical issues in ulcer prevention in primary (Joann
Lohr) and postthrombotic diseases (Seshadri Raju); crit-
ical issues in decreasing re-ulceration rate in primary
(Michel Perrin) and postthrombotic diseases (Peter Pap-
pas); critical issues in deep vein thrombosis (DVT) pre-
vention (Joseph Caprini), in DVT treatment, and pre-
vention of PTS (Mark Meissner, Thomas Wakefield, and
Anthony Comerota); critical issues in diagnosis and in-
vestigation of venous disease (Gregory Moneta); critical
non-medical issues, such as awareness, education, insur-
ance and government policies, and reimbursement struc-
ture (Arun Chopra); and critical issues in relationship
between industry and medical professionals (David
Wright).
The meeting started with a plenary session where
these issues were presented, clarified, and divided into
the four areas of interest of the working groups. Fifty
members of the faculty were then assigned to one of the
four working groups. The focus of the first group was on
issues related to DVT and postthrombotic disease. The
work of this group was lead by Peter Henke and his
co-leader, Tom Wakefield. The second group concen-
trated on primary chronic venous disease (CVD) (leader
Peter Neglen, co-leader Bo Eklof). Issues related to ulcer
healing and recurrences were discussed by the third
group (David Gillespie, leader, and Bob Kistner, co-
leader). The work of the fourth group was dedicated to
nonmedical issues (Mark Passman, leader and Steve
Elias, co-leader).
During the first group session, each of the working
groups analyzed suggested critical issues, proposed ad-
ditional issues, and graded each of the issues by their
importance, practicality, and feasibility. They identified
possible challenges in implementation and listed specific
evidence that is needed to justify each of the critical
issues (regardless of availability of such evidence).
Following the presentation of the group leaders at
the second plenary session, all proposed critical issues
were discussed and compiled.
During the second day of the meeting, the attention
of the audience turned to the analysis of existing evi-
dence. The speakers summarized evidence on specific
topics using the GRADE system to assess the quality of
evidence and the strength of recommendations. The
topics were organized along the lines of group focuses.
The summaries of evidence addressed the effectiveness of
DVT prevention, treatment, and prevention of PTS
(Mark Meissener and Anthony Comerota); definition,
natural history, epidemiology, and effectiveness of treat-
ment of PTS (Suresh Vedantham, Suzan Kahn, Brajesh
K. Lal, and Robert McLafferty); natural history, epidemi-
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(Alun Davies, Eberhard Rabe, and Bill Marston); defini-
tion, effectiveness of treatment of venous ulcers and pre-
vention of re-ulceration (Joe Raffetto, Bradley Bailey, and
Peter Gloviczki); and practical aspects of venous disease as
related to modern healthcare systems, and healthcare poli-
cies (Tom O’Donnell and Robert Zwolak). The evidence
of feasibility of reaching the 50% reduction in venous ulcer
prevalence was presented by Olle Nelzen.
The four working groups continued working revisit-
ing the list of critical issues, identifying issues that have
sufficient support, and gaps of knowledge that needed
immediate attention. They developed specific aims for
each of the critical issues, practical measures to achieve
these aims, the landmark measures of success, and a
timeline for achieving the landmarks. The last two ple-
nary sessions discussed the groups’ proposals and com-
piled a general plan of action.
The writing committee that included the group lead-
ers, and the meeting’s secretary general (Monika Glov-
iczki) had begun its work 6 months before the meeting
by developing standardized reporting forms and pro-
cesses for capturing the details of the discussions. It
continued its work during the conference coordinating
the pace of the group’s progress and ensuring the
achievement of specific aims of each session. The com-
mittee success relied heavily on the outstanding work of
the scribes (Frank Vandy, Aaron Kulwicki, Carolyn
Glass, and Monika Gloviczki). The committee’s work
continued after completion of the meeting. Their analy-
sis and summary of more than 40 hours of discussions
during the 4 days of the PVS6 is presented in this JVS
supplement issue.
The PVS6 initiated a process of coordinated activities
aimed toward reaching a defined and measurable goal.
This process is designed to measure the progress at
specific times, analyze achievements and failures, and
overcome the barriers by identification of new critical
issues and their possible solutions.
The ultimate progress of this process will be mea-
sured by changes in the prevalence of the venous ulcers in
the United States. Such measurement requires an oper-
ational definition of a venous ulcer. This operational
definition may be modified as time goes on, but will
secure consistency in measuring the prevalence of venous
ulcers now and as we progress toward the goal.
Leg ulcers have diverse causes of which venous re-
lated ulcers are the largest group, and within the venous
ulcers are those that have a purely venous etiology and
others that have a combination of causative factors. This
initiative should include only those ulcers in which the
incidence and recurrence can be substantially reduced or
prevented by treating venous disease. Mixed ulcers, ul-
cers caused by injury, and ulcers with healing delayed
mainly due to a severe infection, for example, may re-
quire a substantially different approach to their manage-
ment. Inclusion of these cases in the operational defini-
tion will confuse the issue of whether specific treatmentof the venous component will effectively decrease the
occurrence of the initial and the recurrent ulcer. The
definition should be practical, and require only clinical
information and commonly used tests. Use of venous
pressure measurement, for example, may be desirable,
but is impractical, as only a few laboratories can do such
measurements.
The following operational definition of venous ulcers
for the purpose of measuring and monitoring their prev-
alence was accepted.
Venous ulcer is a wound that meets the following three
criteria:
(1) Location: in lower leg
(2) Presence or history of venous disease: documented
history of DVT, documented axial venous reflux, or
deep vein obstruction
(3) Absence of another condition that could be the essen-
tial cause of the ulcer.
The adaptation of this definition does not undermine
the importance of treatment of venous disease in patients
with mixed ulcers, or chronic wounds of other etiology.
It also does not imply that venous disease in patients that
are not at high risk of ulceration should not be treated, or
that the other hemodynamic abnormalities in legs with
venous ulcers should not be corrected. It is not meant to
be the ultimate definition of the term venous ulcer, but
just serves the purpose of measuring the current (pure
venous) ulcer prevalence, and the success in implement-
ing the proposed plan of action upon the venous com-
ponent of the leg ulcer problem. Future meetings will
analyze this information and make appropriate adjust-
ments to ongoing and new activities.
The success of the PVS6 initiative depends on the
enthusiasm, energy, and contribution of participating
parties. It is an open process, and new participants are
invited to join, new leaders should come forward, and
new projects should be planned.
We hope that this supplement issue of the Journal
provides sufficient information to initiate and sustain an
interest in improving the health of millions of patients by
decreasing the prevalence of a preventable condition,
venous ulceration.
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